97
Participants
Start Date
March 31, 2002
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
BB-10901
dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
Oklahoma University, Oklahoma City
Nevada Cancer Institute, Las Vegas
University of California San Francisco, San Francisco
The Ohio State University Cancer Center and Research Institute, Columbus
M. D. Anderson Cancer Center at University of Texas, Houston
Fred Hutchinson Cancer Research Center, Seattle
Christie Hospital NHS Trust, Manchester
Cancer Research Centre at Weston Park Hospital, Sheffield
Royal Marsden NHS Foundation Trust - Surrey, Sutton
Lead Sponsor
ImmunoGen, Inc.
INDUSTRY